Gathering the record
Relay is organizing the evidence and source boundaries.
Experimental synthetic pentadecapeptide
BPC-157 is an experimental 15-amino-acid peptide promoted for tissue repair and gut health. Most supporting evidence comes from animals or laboratory models. Published human reports are small and uncontrolled, while a new Phase 2 hamstring-strain trial is recruiting without results.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
BPC-157 is an unapproved synthetic peptide widely associated online with healing and recovery claims. Its exact molecular action in people has not been established.
Animal and laboratory findings suggest possible effects on tissue repair and inflammation, prompting interest in whether any of those signals translate to people. Researchers also need to determine whether material sold under this name is chemically consistent.
Human evidence is limited to very small pilots, meeting abstracts, and uncontrolled reports using several different administration methods. No large randomized human efficacy trial has established healing benefit.
Human absorption, repeated-use safety, subcutaneous administration, product identity, possible immune reactions, and clinical benefit remain unresolved. Animal findings cannot establish a human amount, preparation, or treatment effect.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
FDA's review found only small, heterogeneous human reports using rectal, intra-articular, intravesical, or intravenous administration—not a verified subcutaneous human study.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Several small human reports, one historical controlled abstract, and a recruiting Phase 2 trial sit beneath a much larger preclinical literature.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human findings are too small, uncontrolled, incomplete, or unpublished to establish injury healing, gastrointestinal benefit, or population safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: FDA found no human studies using the proposed oral, subcutaneous, nasal, or transdermal routes. The small reports do not establish clinical benefit, repeated-use safety, product identity, reconstitution, or stability. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 53-person randomized ulcerative-colitis study is known only through a meeting abstract summarized by FDA and was judged insufficient to support effectiveness. The published full papers are smaller uncontrolled reports.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether BPC-157 improves objective healing, function, return-to-activity time, or meaningful gastrointestinal outcomes in controlled human trials, and whether repeated exposure is safe.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Researchers have proposed effects involving growth-factor signaling, angiogenesis, inflammatory signaling, and nitric-oxide pathways, but FDA's 2026 review says the molecular targets remain unidentified and the mechanism is unknown.
The published papers cover knee pain, interstitial cystitis, and a two-person IV safety pilot. None is a large randomized efficacy trial.
FDA located a 53-person controlled study only as a meeting abstract. The reported between-group estimate was imprecise, and critical methods and follow-up details were missing.
The registered trial plans to compare BPC-157 with placebo alongside the same rehabilitation program, using return-to-sport time and MRI injury volume as co-primary endpoints.
FDA's July 2026 review found no human studies using those proposed routes and said the available clinical safety information is insufficient.
Rat tendon, muscle, ligament, gastrointestinal, and vascular models report favorable signals. Translation to faster healing, better function, or lower reinjury risk in people remains unproven.
The Pharmacy Compounding Advisory Committee voted to recommend BPC-157 free base and acetate for possible 503A Bulks List inclusion. The recommendation is non-binding, the final FDA decision was pending at the cutoff, and compounding status is separate from drug approval.
The 2026 Prohibited List names BPC-157 among non-approved substances prohibited at all times.
Mechanisms
BPC-157 is a synthetic pentadecapeptide associated with the sequence GEPPPGKPADDAGLV. Preclinical papers propose effects involving angiogenesis, growth-factor signaling, inflammatory mediators, nitric-oxide pathways, fibroblast behavior, and vascular responses. FDA's 2026 review concluded that no molecular target has been identified and the mechanism remains unknown. The human evidence base consists mainly of small observational reports, a two-person safety pilot, an incompletely reported historical ulcerative-colitis study, and registered trials without evaluable results.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Open-label, two-person intravenous safety observation
Two healthy adults
The two participants had no reported adverse effects or meaningful short-term laboratory changes during the pilot.
Study administration: Intravenous BPC-157 10 mg on day 1 and 20 mg on day 2 under the pilot protocol
Limitations: Two people, no placebo, no blinding, short observation, and no efficacy endpoint. This cannot establish a population safety profile or support other routes.
Single-center retrospective pilot without placebo or blinded assessment
Twelve women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate
Ten of 12 participants reported complete symptom resolution and two reported 80% improvement after the procedure.
Study administration: One intravesical treatment session containing 10 mg BPC-157 under the study protocol
Limitations: No control group, very small sample, retrospective design, subjective outcomes, and limited follow-up. The report does not establish efficacy or long-term safety.
Uncontrolled retrospective chart review with follow-up questions
Seventeen people treated for heterogeneous chronic knee-pain conditions
Sixteen people were reached for follow-up and 14 reported some relief. The report did not use a control group, blinded assessment, standardized pain scale, or follow-up imaging.
Study administration: One or two intra-articular injections containing 2–4 mg BPC-157; the first four patients also received thymosin beta-4
Limitations: Very small retrospective series with self-reported outcomes, mixed knee diagnoses, selection bias, and treatment confounding in the first four patients. It cannot establish tissue healing or causal efficacy.
Controlled rat Achilles-tendon transection experiments with related in-vitro tendocyte work
Rats with surgically transected Achilles tendons
The study reported improved biomechanical, functional, microscopic, and macroscopic healing measures in the rat model.
Study administration: Experimental BPC-157 regimens versus control conditions in rats and cultured tendocytes
Limitations: Animal and cell findings demonstrate biological plausibility, not human injury-healing efficacy. The study does not validate consumer dosing, route, formulation, or safety.
Multicenter, randomized, double-blind, placebo-controlled exploratory study summarized by FDA from a 2005 meeting abstract
Adults with mild-to-moderate ulcerative colitis
FDA reported mean Disease Activity Index changes of −3.2 with BPC-157 and −1.6 with placebo. The estimated between-group difference was 1.6 points with a 95% confidence interval from −4.84 to 1.62.
Study administration: BPC-157 80 mg rectal enema or placebo once daily under the historical study protocol
Limitations: Only a meeting abstract was available. FDA found important design and analysis details missing and concluded that the evidence was insufficient to support effectiveness for ulcerative colitis.
Randomized, double-blind, placebo-controlled, parallel-group trial with standardized rehabilitation
Adults aged 18–45 with MRI-confirmed acute grade II hamstring strain
No results are posted. The registration describes the first sizable controlled human trial designed to test whether BPC-157 adds benefit to a standardized rehabilitation program.
Study administration: Once-daily subcutaneous investigational BPC-157 or matching placebo for 14 days; dose is not disclosed in the public registration
Limitations: A recruiting trial is evidence that a question is being studied—not evidence that the treatment works or is safe. Enrollment, completion, and results remain pending.
Registered safety and pharmacokinetics study with BPC-157/Bepecin and placebo
Healthy volunteers aged 18–35
ClinicalTrials.gov does not provide posted results that can be independently evaluated.
Study administration: BPC-157/Bepecin and placebo as listed in the registry; interpretable dosing and results are not publicly posted
Limitations: The record's status is shown as unknown and no results are posted. Registration alone cannot establish safety, pharmacokinetics, or efficacy.
Safety snapshot
Human subcutaneous, oral, nasal, and transdermal pharmacokinetics and safety are not established by published evidence.
No direct evidenceAbsence of adequate evidence is not proof of safety and is not proof of harm; it means the question is unresolved.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved. The Pharmacy Compounding Advisory Committee recommended possible 503A Bulks List inclusion on July 23, 2026; final FDA action remained pending at the evidence cutoff. BPC-157 remains prohibited under WADA S0. Whether BPC-157 improves objective healing, function, return-to-activity time, or meaningful gastrointestinal outcomes in controlled human trials, and whether repeated exposure is safe.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-23
2026-07-23
2026-02-27 · NCT07437547
2026-01-01
2025-09-01 · PMID 40131143
2025-08-06 · PMID 40756949 · DOI 10.1177/15563316251355551
2024-10-01 · PMID 39325560
2021-07-01 · PMID 34324435
2015-12-22 · NCT02637284
2003-11-01 · PMID 14554208 · DOI 10.1016/S0736-0266(03)00110-4